On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post polycythemia vera and post essential thrombocythemia), in adults with anemia.
The FDA had approved momelotinib to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (
Myelofibrosis is a reactive and reversible process common to many malignant and benign bone marrow disorders. It can present de novo as primary myelofibrosis (PMF), or as secondary (reactive) myelofibrosis if caused by another disorder, drug treatment, or toxic agent.
Myelofibrosis is a reactive and reversible process common to many malignant and benign bone marrow disorders. It can present de novo as primary myelofibrosis (PMF), or as secondary (reactive) myelofibrosis if caused by another disorder, drug treatment, or toxic agent.
treatment for primary myelofibrosis (MF) drugs in development. The structure of the part of JAK2 that causes
Emerging drugs for the treatment of Myelofibrosis. Shreenivas A, Mascarenhas Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.
drug as part of a global clinical trial aimed at improving treatment for myelofibrosis. drugs, and offer consenting patients access to
Description and Brand Names. Drug information provided by: Merative, Micromedex US Brand Name. Jakafi; Descriptions. Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Currently, there are few Food and Drug Administration-approved drugs for the treatment of myelofibrosis. Available options provide patients
Comments
4*